Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZNTL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsZentalis Pharmaceuticals reports Q1 2026 financial results and business updates
Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
high
Company announced financial results for the quarter ended March 31, 2026, along with business updates. Specific metrics are contained in the press release furnished as an exhibit.
Item 2.02 verify on EDGAR → -
low
Zentalis furnished a corporate presentation for use at investor conferences and analyst meetings beginning May 12, 2026, ensuring public access to materials shared in private meetings.
Item 7.01 verify on EDGAR →
Summary
Zentalis Pharmaceuticals disclosed its first quarter 2026 financial results on May 12, 2026, covering the period ended March 31, 2026. The company also provided business updates in the accompanying press release. This is a routine quarterly earnings disclosure that biotech investors typically monitor for cash runway, clinical trial progress, and operational milestones.
Additionally, the company furnished a corporate presentation that management will use at upcoming investor conferences and meetings. This is standard Regulation FD practice to ensure all investors have equal access to information being shared with analysts and institutional investors.
Retail investors should review the actual press release and presentation exhibits for specific financial metrics, cash position, and pipeline updates. Key items to watch include any changes to clinical trial timelines, regulatory milestones, or cash burn rate that could affect the company's funding needs.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 12, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026, and commented on certain business updates.
The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026, along with business updates. The specific financial metrics and business commentary are contained in the referenced press release (Exhibit 99.1), which is not included in this 8-K body text.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Beginning May 12, 2026, spokespersons of the Company plan to present the information in the Corporate Presentation furnished as Exhibit 99.2 to this Current Report and incorporated herein by reference at conferences and in meetings with investors and analysts.
The company is furnishing a corporate presentation that will be used by company representatives at investor conferences and analyst meetings. This is a routine Regulation FD disclosure to ensure all investors have access to the same presentation materials being shared in private meetings.
Event · Item 9.01 — Financial Statements and Exhibits
Zentalis filed an 8-K furnishing a press release and corporate presentation dated May 2026, with no material business event disclosed.
Added in current filing · verify on EDGAR →
The following exhibit relating to Items 2.02 and 7.01 shall be deemed to be furnished, and not filed:
Exhibit No. Description
99.1 Press Release issued on May 12, 2026
99.2 Corporate Presentation dated May 2026
The company furnished a press release and corporate presentation dated May 2026 under Items 2.02 and 7.01. These items typically relate to results of operations and financial condition (2.02) or regulation FD disclosure (7.01). Without the actual exhibit content, the materiality and substance of the disclosure cannot be determined from this 8-K body alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify